<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02079805</url>
  </required_header>
  <id_info>
    <org_study_id>279/NRP-001</org_study_id>
    <secondary_id>U1111-1151-7168</secondary_id>
    <secondary_id>AZI-P4-004</secondary_id>
    <secondary_id>JapicCTI-142461</secondary_id>
    <nct_id>NCT02079805</nct_id>
  </id_info>
  <brief_title>A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R</brief_title>
  <official_title>A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, randomized, open-label, parallel-group exploratory study to explore the effects
      of azilsartan (Azirva), compared with telmisartan, on insulin resistance in participants with
      essential hypertension complicated by type 2 diabetes mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the present study is to explore the effects of azilsartan 20 mg,
      compared with telmisartan 40 mg, once daily orally for 12 weeks on insulin resistance in
      participants with essential hypertension complicated by type 2 diabetes mellitus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Insulin Resistance Index (HOMA-R) From Baseline at the End of the Treatment Period (Week 12)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from the start of the treatment period (baseline) at the end of the treatment period (Week 12) was reported. Insulin Resistance Index (HOMA-R) measures insulin resistance, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Blood Glucose From Baseline at the End of the Treatment Period (Week 12)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline in fasting blood glucose values collected at week 12 or final visit relative to baseline was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Insulin From Baseline at the End of the Treatment Period (Week 12)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline in fasting insulin values collected at week 12 or final visit relative to baseline was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycosylated Hemoglobin (HbA1c) From Baseline at the End of the Treatment Period (Week 12)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline in the values of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit relative to baseline was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis Model Assessment of Beta Cell Function (HOMA-β) From Baseline at the End of the Treatment Period (Week 12)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline in HOMA-β collected at week 12 or final visit relative to baseline was reported. Homeostasis model assessment of beta cell function measures as following; HOMA-β = fasting insulin (μU/mL) ×360/{fasting glucose (mg/dL) - 63}.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 1,5-anhydroglucitol (1,5-AG) From Baseline at the End of the Treatment Period (Week 12)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline in 1,5-G concentration collected at week 12 or final visit relative to baseline was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Essential Hypertension Complicated by Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Azilsartan 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive azilsartan 20 mg once daily in the morning before or after breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive telmisartan 40 mg once daily in the morning before or after breakfast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan</intervention_name>
    <description>Azilsartan tablets</description>
    <arm_group_label>Azilsartan 20 mg</arm_group_label>
    <other_name>Azilva Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Telmisartan tablets</description>
    <arm_group_label>Telmisartan 40 mg</arm_group_label>
    <other_name>Micardis Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The participant was given the diagnosis of grade I or II essential hypertension and
             was judged by the principal investigator or investigator that they can be
             appropriately treated with azilsartan 20 mg and telmisartan 40 mg.

          2. Sitting systolic blood pressure of ≥ 130 mmHg and &lt; 180 mmHg or sitting diastolic
             blood pressure of ≥ 80 mmHg and &lt; 110 mmHg at the start of the treatment period (Week
             0) Sitting blood pressure will be measured until 2 consecutive stable measurements are
             obtained (i.e., the difference between 2 measurements: diastolic blood pressure of &lt;5
             mmHg and systolic blood pressure of &lt; 10 mmHg) after resting in a sitting position for
             at least 5 minutes. The average value of the last 2 measurements will be recorded (the
             first the decimal place is rounded off).

          3. Type 2 diabetes mellitus

          4. HbA1c (NGSP (National Glycohemoglobin Standardization Program) value) of &lt; 8.4% during
             3 months before informed consent, with a ≤ 0.3% change in HbA1c (peak minus nadir)
             during 3 months before informed consent

          5. No change in diet/exercise therapy during the 3 months before the informed consent in
             a participant who has been on diet/exercise therapy and instructed to improve life
             style (e.g., diet and exercise)

          6. Age ≥ 20 years at the time of consent

          7. Outpatients

          8. Capable of providing written consent before participation in this study.

        Exclusion Criteria:

          1. Grade III essential hypertension (i.e., sitting systolic blood pressure 180 mmHg or
             sitting diastolic blood pressure ≥ 110 mmHg), secondary hypertension, or malignant
             hypertension.

          2. Grade II essential hypertension (i.e., sitting systolic blood pressure ≥ 160 mmHg or
             sitting diastolic blood pressure ≥ 100 mmHg) for which antihypertensive drug(s) are
             used

          3. Use of oral antihypertensive medication within 2 weeks before the start of the
             treatment period Participants who are on any antihypertensive agent at the time of
             informed consent can be enrolled in the study only after 2-week washout following
             informed consent.

          4. Use of RAS inhibitors or thiazolidines within 3 months before the start of the
             treatment period

          5. Type 1 diabetes mellitus

          6. Fasting blood glucose of &lt; 180 mg/dL and HOMA-R of ≤ 1.6 at the start of the treatment
             period (Week 0)

          7. Receiving or requiring any of the following at the time of informed consent:

               -  Insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, or other parenteral
                  hypoglycemic agents

               -  Combination therapy with 3 or more oral hypoglycemic agents

          8. Change of antidiabetic medication (including dosage change) within 3 months before the
             start of the treatment period

          9. Having diagnosed/treated any of the following cardiovascular diseases within 3 months
             before the start of the treatment period:

               -  Cardiac disease/condition: myocardial infarction, coronary revascularization
                  procedure

               -  Cerebrovascular disease: cerebral infarction, cerebral haemorrhage, transient
                  ischaemic attack

               -  Advanced hypertensive retinopathy (retinal bleeding or oozing, papilloedema)

         10. Having diagnosed/treated for any of the following cardiovascular diseases more than 3
             months before the start of the treatment period, and is now still in unstable
             condition.

               -  Cardiac disease/condition: myocardial infarction, coronary revascularization
                  procedure

               -  Cerebrovascular disease: cerebral infarction, cerebral haemorrhage, transient
                  ischaemic attack

         11. Past or current history of any of the following cardiovascular diseases.

               -  Cardiac valve stenosis

               -  Angina pectoris requiring medication

               -  Congestive cardiac failure requiring medication

               -  Arrhythmia requiring medication (e.g., paroxysmal atrial fibrillation, severe
                  bradycardia, torsade de pointes, and ventricular fibrillation)

               -  Arteriosclerosis obliterans with intermittent claudication or other symptoms

         12. Have severe ketosis, diabetic coma or precoma, severe infection, or serious trauma

         13. Clinically evident renal disorder (e.g., eGFR &lt;30 mL/min/1.73 m2)

         14. Markedly low bile secretion or severe hepatic disorder

         15. History of hypersensitivity or allergy to azilsartan or telmisartan or to both.

         16. Presence of hyperkalemia (potassium level ≥ 5.5 mEq/L on laboratory testing)

         17. Currently participating in any other clinical study.

         18. Pregnant women, women with possible pregnancy, or breast-feeding women.

         19. Other participants who are inappropriate for participation in this study in the
             opinion of the principal investigator or investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kyoto-Shi</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2014</study_first_posted>
  <results_first_submitted>April 24, 2017</results_first_submitted>
  <results_first_submitted_qc>April 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 2, 2017</results_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 27 investigative sites in Japan, from 04 June 2014 to 25 April 2016.</recruitment_details>
      <pre_assignment_details>Participants with diagnosis of type 2 diabetes mellitus were enrolled in 2 treatment group: Azilsartan 20 mg, and Telmisartan 40 mg for 12 weeks as treatment period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Telmisartan 40 mg</title>
          <description>Participants received telmisartan 40 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
        </group>
        <group group_id="P2">
          <title>Azilsartan 20 mg</title>
          <description>Participants received azilsartan 20 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pretreatment Event/Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Set included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Telmisartan 40 mg</title>
          <description>Participants received telmisartan 40 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
        </group>
        <group group_id="B2">
          <title>Azilsartan 20 mg</title>
          <description>Participants received azilsartan 20 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.3" spread="9.10"/>
                    <measurement group_id="B2" value="63.2" spread="12.76"/>
                    <measurement group_id="B3" value="64.2" spread="11.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.95" spread="16.689"/>
                    <measurement group_id="B2" value="70.41" spread="14.878"/>
                    <measurement group_id="B3" value="70.67" spread="15.534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index = weight (kg)/[height (m)^2]</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.18" spread="3.720"/>
                    <measurement group_id="B2" value="27.19" spread="4.642"/>
                    <measurement group_id="B3" value="27.19" spread="4.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Classification</title>
          <description>Participants who answered Yes or No for a question &quot;Drik Alcohol Almost Everyday?&quot; were reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Hypertention</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.71" spread="4.391"/>
                    <measurement group_id="B2" value="3.54" spread="4.392"/>
                    <measurement group_id="B3" value="4.11" spread="4.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes Mellitus</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.53" spread="4.279"/>
                    <measurement group_id="B2" value="4.89" spread="5.039"/>
                    <measurement group_id="B3" value="4.72" spread="4.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Taking Biguanides</title>
          <description>Participants who had taken biguanides when study started were reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Had taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not had taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin Resistance Index (HOMA-R)</title>
          <description>Insulin Resistance Index (HOMA-R) measures insulin resistance, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance.</description>
          <units>HOMA-R Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.31" spread="1.366"/>
                    <measurement group_id="B2" value="4.24" spread="1.843"/>
                    <measurement group_id="B3" value="3.79" spread="1.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood Pressure Systolic Mean</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145.6" spread="9.91"/>
                    <measurement group_id="B2" value="143.3" spread="9.28"/>
                    <measurement group_id="B3" value="144.4" spread="9.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood Pressure Diastolic Mean</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.3" spread="10.61"/>
                    <measurement group_id="B2" value="88.8" spread="7.19"/>
                    <measurement group_id="B3" value="89.0" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin (HbA1c)</title>
          <description>Glycosylated Hemoglobin (HbA1c) were caluculated by the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.63" spread="0.411"/>
                    <measurement group_id="B2" value="6.81" spread="0.488"/>
                    <measurement group_id="B3" value="6.72" spread="0.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Insulin Resistance Index (HOMA-R) From Baseline at the End of the Treatment Period (Week 12)</title>
        <description>Change from the start of the treatment period (baseline) at the end of the treatment period (Week 12) was reported. Insulin Resistance Index (HOMA-R) measures insulin resistance, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The full analysis set was defined as the participants who received at least 1 dose of the study drug for the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg</title>
            <description>Participants received telmisartan 40 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan 20 mg</title>
            <description>Participants received azilsartan 20 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Resistance Index (HOMA-R) From Baseline at the End of the Treatment Period (Week 12)</title>
          <description>Change from the start of the treatment period (baseline) at the end of the treatment period (Week 12) was reported. Insulin Resistance Index (HOMA-R) measures insulin resistance, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405).</description>
          <population>The full analysis set was defined as the participants who received at least 1 dose of the study drug for the treatment period.</population>
          <units>HOMA-R Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.928"/>
                    <measurement group_id="O2" value="0.22" spread="2.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Telmisartan 40 mg, Azilsartan 20 mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Blood Glucose From Baseline at the End of the Treatment Period (Week 12)</title>
        <description>Change from baseline in fasting blood glucose values collected at week 12 or final visit relative to baseline was reported.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The full analysis set was defined as the participants who received at least 1 dose of the study drug for the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg</title>
            <description>Participants received telmisartan 40 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan 20 mg</title>
            <description>Participants received azilsartan 20 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Blood Glucose From Baseline at the End of the Treatment Period (Week 12)</title>
          <description>Change from baseline in fasting blood glucose values collected at week 12 or final visit relative to baseline was reported.</description>
          <population>The full analysis set was defined as the participants who received at least 1 dose of the study drug for the treatment period.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.06" spread="14.991"/>
                    <measurement group_id="O2" value="2.00" spread="18.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Insulin From Baseline at the End of the Treatment Period (Week 12)</title>
        <description>Change from baseline in fasting insulin values collected at week 12 or final visit relative to baseline was reported.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The full analysis set was defined as the participants who received at least 1 dose of the study drug for the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg</title>
            <description>Participants received telmisartan 40 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan 20 mg</title>
            <description>Participants received azilsartan 20 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Insulin From Baseline at the End of the Treatment Period (Week 12)</title>
          <description>Change from baseline in fasting insulin values collected at week 12 or final visit relative to baseline was reported.</description>
          <population>The full analysis set was defined as the participants who received at least 1 dose of the study drug for the treatment period.</population>
          <units>µU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.818" spread="2.7623"/>
                    <measurement group_id="O2" value="0.475" spread="6.3847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycosylated Hemoglobin (HbA1c) From Baseline at the End of the Treatment Period (Week 12)</title>
        <description>Change from baseline in the values of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit relative to baseline was reported.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The full analysis set was defined as the participants who received at least 1 dose of the study drug for the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg</title>
            <description>Participants received telmisartan 40 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan 20 mg</title>
            <description>Participants received azilsartan 20 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycosylated Hemoglobin (HbA1c) From Baseline at the End of the Treatment Period (Week 12)</title>
          <description>Change from baseline in the values of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit relative to baseline was reported.</description>
          <population>The full analysis set was defined as the participants who received at least 1 dose of the study drug for the treatment period.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.290"/>
                    <measurement group_id="O2" value="0.09" spread="0.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Homeostasis Model Assessment of Beta Cell Function (HOMA-β) From Baseline at the End of the Treatment Period (Week 12)</title>
        <description>Change from baseline in HOMA-β collected at week 12 or final visit relative to baseline was reported. Homeostasis model assessment of beta cell function measures as following; HOMA-β = fasting insulin (μU/mL) ×360/{fasting glucose (mg/dL) - 63}.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The full analysis set was defined as the participants who received at least 1 dose of the study drug for the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg</title>
            <description>Participants received telmisartan 40 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan 20 mg</title>
            <description>Participants received azilsartan 20 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Homeostasis Model Assessment of Beta Cell Function (HOMA-β) From Baseline at the End of the Treatment Period (Week 12)</title>
          <description>Change from baseline in HOMA-β collected at week 12 or final visit relative to baseline was reported. Homeostasis model assessment of beta cell function measures as following; HOMA-β = fasting insulin (μU/mL) ×360/{fasting glucose (mg/dL) - 63}.</description>
          <population>The full analysis set was defined as the participants who received at least 1 dose of the study drug for the treatment period.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.88" spread="20.151"/>
                    <measurement group_id="O2" value="-0.44" spread="30.985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 1,5-anhydroglucitol (1,5-AG) From Baseline at the End of the Treatment Period (Week 12)</title>
        <description>Change from baseline in 1,5-G concentration collected at week 12 or final visit relative to baseline was reported.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The full analysis set was defined as the participants who received at least 1 dose of the study drug for the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg</title>
            <description>Participants received telmisartan 40 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan 20 mg</title>
            <description>Participants received azilsartan 20 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 1,5-anhydroglucitol (1,5-AG) From Baseline at the End of the Treatment Period (Week 12)</title>
          <description>Change from baseline in 1,5-G concentration collected at week 12 or final visit relative to baseline was reported.</description>
          <population>The full analysis set was defined as the participants who received at least 1 dose of the study drug for the treatment period.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="2.143"/>
                    <measurement group_id="O2" value="-0.66" spread="2.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events</title>
        <time_frame>Up to Week 12</time_frame>
        <population>The safety analysis set was defined as the participants who received at least 1 dose of the study drug for the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg</title>
            <description>Participants received telmisartan 40 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan 20 mg</title>
            <description>Participants received azilsartan 20 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events</title>
          <population>The safety analysis set was defined as the participants who received at least 1 dose of the study drug for the treatment period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 12</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Telmisartan 40 mg</title>
          <description>Participants received telmisartan 40 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
        </group>
        <group group_id="E2">
          <title>Azilsartan 20 mg</title>
          <description>Participants received azilsartan 20 mg, once daily in the morning before or after breakfast for 12 weeks as treatment priod.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutaneous amyloidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

